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Triangle Park, NC, Bracknell, United Kingdom, and Vancouver, British Columbia, CanadaBackground: The Asthma Quality of Life Questionnaire
(AQLQ) and the Asthma Control Questionnaire (ACQ) are
widely used in asthma research; however, in studies of newer
asthma treatments, mean improvements in these measures
compared with placebo arms do not exceed the minimal
important difference (MID), particularly when a new treatment
is added to current treatment.
Objective: We performed a systematic review and network
meta-analysis to examine the magnitude of AQLQ and ACQ
responses achieved with commonly used asthma drugs and
factors influencing these end points in clinical trials.
Methods: A systematic literature search was conducted to
identify blinded randomized controlled trials reporting AQLQ
or ACQ results. Mixed treatment comparisons, combined with
meta-regression, were then performed.
Results: Of the 64 randomized controlled trials (42,527 patients)
identified, 54 included the AQLQ and 11 included the ACQ as
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914treatment during the run-in period, concurrent treatment
during the treatment period, and instrument version
significantly influenced the change in AQLQ score from baseline
and whether it exceeded the MID. When compared with
placebo, only inhaled corticosteroids (ICSs), with or without a
long-acting b-agonist, achieved the MID. The ACQ results were
comparable with those of the AQLQ: no differences from
placebo exceeded the MID, and ICS-based treatments provided
the greatest improvements.
Conclusion: The established within-patient MID for the ACQ
and AQLQ is not achievable as a group-wise efficacy threshold
between treatment arms in clinical studies in which controllers
are added to ICS treatment. Thus in addition to reporting mean
changes of the instruments, other measurement criteria should
be considered, including responder analyses. (J Allergy Clin
Immunol 2015;136:914-22.)
Key words: Asthma, asthma control, quality of life, network
meta-analysis, questionnaire
The step-wise approach to pharmacotherapy in patients with
asthma involves addition of therapy with the goal of achieving
both symptom control and prevention of exacerbations.1
However, evaluating the efficacy of adding 1 or more controllers
to inhaled corticosteroids (ICSs) at step 3 and beyond in the
treatment guidelines is challenging for several reasons. Generally,
the incremental benefit achieved with each addition is likely to
diminish as more treatments are added. Furthermore, because
treatments differ in their effect on different asthma end points,
improvement might be limited to some, but not all, end points.
Demonstrating improvement in patient-reported outcomes
(PROs), such as symptom control and health status, is particularly
challenging because these outcomes are subjective and can vary
widely among subjects. Consequently, their measurement
involves the use of complex tools for semiquantitative assessment
of symptoms and impairment. Health authorities might require
evidence of improvement in 1 or more patient-reported end points
for registration, reimbursement, or both of new asthma
treatments. Widely used PROs in clinical trials are the Asthma
Control Questionnaire (ACQ)2,3 and the Asthma Quality of Life
Questionnaire (AQLQ).4 For both instruments, the accepted
minimal important difference (MID) is 0.5 units,5,6 which is the
‘‘smallest difference in score . which patients perceive as
beneficial and which would mandate a change in the patient’s
management.’’5 The MID is a measure of within-person
change but in clinical trials is used as a threshold value for
between-group comparisons.7
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controller treatments in patients with severe asthma (eg,
omalizumab and tiotropium) reveals that improvements in
AQLQ and ACQ responses are smaller than might be expected.8,9
For example, in trials of tiotropium in patients whose symptoms
are uncontrolled with at least an ICS and a long-acting b-agonist
(LABA), group mean differences in AQLQ and ACQ scores
compared with placebo did not exceed the MID for either
instrument. These observations call into question the performance
of these instruments and the interpretation of results obtainedwith
them, particularly when multiple treatments are being used.9 It is
worth noting that both the AQLQ and the ACQ were developed
and their reliability, validity, and responsiveness were assessed
in a patient population that was largely steroid naive or receiving
ICSs alone.4,5,10,11
The MID for clinical outcomes is estimated by means of a
process of triangulation that compares the outcome of interest
with changes in other measures to arrive at the smallest difference
that might represent benefit.12 At both the group and individual
levels, the MID might depend on the clinical context and patient
management decision at hand, the baseline fromwhich the patient
starts, and whether the patient’s symptoms are improving or
deteriorating.13 The initial derivation of the MID for both the
AQLQ and the ACQ was based largely on the physician’s
judgment of change in patients whose symptoms improved on
monotherapy with an ICS, with placebo as a control. To the
authors’ knowledge, the MID has not been correlated with other
important measures of interest in asthma, such as exacerbations
or the frequency of hospitalization. Furthermore, to date, there
has been no critical review of the extent to which the MID is
achievable when treatments are added to highly effective
medications, such as ICSs or ICS plus LABA combinations.
We report here a systematic review and meta-analysis of
clinical trials in patients with asthma in which the AQLQ, ACQ,
or both was used to examine the achievability of between-group
mean differences of 0.5 or more with established asthma
treatments.METHODS
Search strategy
A systematic literature search using PubMed, Embase, and the National
Health Service Economic Evaluation Database was conducted on April 5,
2012, and updated on June 14, 2013 (details are provided in the Methods
section and Table E1 in this article’s Online Repository at www.jacionline.
org). In addition, the bibliographies of existing literature reviews and
meta-analyses, the clinicaltrials.gov study register, and the 2011 and 2012
conference Web sites of the American Thoracic Society and European
Respiratory Society were searched. No limits regarding publication date or
language were applied.Inclusion criteria and selection of studies
Using predefined inclusion and exclusion criteria, 2 reviewers (C.C. and
M.F.) independently scanned titles and abstracts of the identified studies at
level 1 screening to evaluate potential study relevance; full texts of studies
selected at level 1 were reviewed at level 2 screening (see the Methods section
in this article’s Online Repository for full details). Discrepancies were
reconciled between the 2 reviewers or by a third reviewer (D.E.), if necessary.
Double-blind randomized controlled trials (RCTs) of adolescent and adult
patients with uncontrolled, symptomatic, or persistent asthma at baselinewere
included if the overall score changes from baseline values for the AQLQ,
ACQ, or both were reported after patients received 1 or more of the following
treatments: an ICS, a LABA, a leukotriene receptor antagonist (LTRA), a
short-acting b-agonist, omalizumab, or theophylline. Data from all the
instrument versions of the AQLQ, such as the Standardized AQLQ and the
MiniAQLQ,10,11 and of the ACQ, such as the 5-item and 6-item versions
(ACQ-5 and ACQ-6),6 were collected.
Data extraction and assessment of risk of bias
Data from the original studies were extracted by using a standardized
abstraction form developed inMicrosoft Excel (see theMethods section in this
article’s Online Repository for details), which included study design informa-
tion. To consistently capture key study differences, run-in and background
treatments were defined as stable comedications if they were taken by at least
50% of patients in addition to the study medication before randomization,
after randomization, or both. Data were independently checked for accuracy
by 2 reviewers (C.C. and M.F.); the risk of bias of individual studies was as-
sessed at the study and outcome level by using the quality criteria presented
in the National Institute for Health and Care Excellence single technology
appraisal guidance14 and the Centre for Reviews and Dissemination’s guid-
ance (see theMethods section in this article’s Online Repository for details).15Outcome measures
The meta-analysis assessed AQLQ and ACQ score changes from baseline,
where baseline was defined as the last visit before the start of the treatment
phase. The extracted assessments were based on the time point of the study
primary end point, as designated in the publication, or the latest available time
point (if no time point was designated as primary).Statistical methods
For each outcome, a mixed treatment comparison (MTC) combined with
meta-regression was performed. Linear mixed models with the SE of mean
change from baseline in the instrument used as a weighting variable and trials
as random effects were constructed by using the PROC MIXED procedure in
SAS (version 9.3; SAS Institute, Cary, NC). If the SE was not available, it was
either derived or imputed (see the Methods section in this article’s Online
Repository for details). Adjusted least-squares means for each treatment and
adjusted mean differences between any 2 treatments, along with 95% CIs,
were estimated. Multiple covariates were assessed, both individually and in
combination, for inclusion in the MTC model to address heterogeneity16
and reduce inconsistency between treatment comparisons (see the Methods
section in this article’s Online Repository for details).17 Covariates with
P values of .05 or less were included in the model.
By comparing the estimated mean changes from baseline and their CIs with
theMID,18 the size of the treatment responses were further classified as follows:
 no effect if the point estimate did not reach the MID and the 95% CI
included zero;
 no clinically significant effect if the point estimate did not reach the MID
and the 95% CI was between zero and the MID;
 not significantly less than the MID if the point estimate did not reach the
MID and the 95% CI was greater than zero but contained the MID;
 probable clinically significant effect if the point estimate exceeded the
MID but the 95% CI contained the MID; and
 large clinically significant effect if the point estimate exceeded the MID
and the 95% CI exceeded the MID.
FIG 1. Flow diagram of study selection. *The update of the database systematic search was conducted from
March 26, 2012, to June 14, 2013, with the objective of capturing additional blind RCTs. Only blind RCTs
identified in this search were included in the meta-analysis. NHS EED, National Health Service Economic
Evaluation Database.
TABLE I. Summary of baseline characteristics
Treatment No. of studies No. of patients
Mean
age (y)
Mean body mass
index (kg/m2)
Reversibility*
(%)
Female
(%)
White
(%)
Never
smoked (%)
Baseline mean
FEV1 (L)
ICS 33 8,525 40.3 26.6 23.0 59.0 77.0 80.9 2.32
LABA 17 4,811 40.2 NA 22.0 57.8 81.6 NA 2.31
ICS 1 LABA 25 14,988 41.2 27.7 23.6 60.2 54.9 81.6 2.21
LTRA 19 5,336 37.5 NA 17.8 56.6 78.3 74.4 2.43
SABA 5 1,763 41.6 NA 23.3 59.1 NA NA 2.18
Omalizumab 6 1,407 41.5 NA 24.6 58.5 80.4 76.2 2.58
Theophylline 1 161 41.0 NA NA 75.0 60.0 NA NA
Placebo 33 5,536 39.1 NA 25.0 57.0 78.8 79.5 2.40
All treatments 64 42,527 40.2 26.7 22.9 58.8 73.5 80.3 2.3
NA, Data not available; SABA, short-acting b-agonist.
*Reversibility as the mean percentage increase in FEV1 after b2-agonist inhalation at baseline or screening.
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for the SE and the effect of including in the analysis studies that compared
treatments within the same treatment classes. Inconsistency of the network
was also evaluated.19-21 A test result was declared significant if theP valuewas
.05 or less.
RESULTS
Systematic review and summary of included trials
Sixty articles reporting on 64 RCTs (42,527 patients) were
identified (see Fig 1 and the Results section in this article’s Online
Repository at www.jacionline.org for details).Table I presents a weighted average of the baseline
characteristics by treatment. In general, baseline characteristics
were similar across treatments.
Overall, the quality of the studies was good (see Table E2 in this
article’s Online Repository at www.jacionline.org). Most studies
reported the differences in dropouts between the treatment groups
and the reasons for patient withdrawal, although reporting of
randomization methods, concealment allocation, and blinding
of participants was not clear in many of the studies. The risk of
bias in the analyses was not clear in several studies because the
conduct of intention-to-treat analyses was poorly described and
FIG 2. AQLQ network of evidence. Numbers indicate the number of studies with comparisons of AQLQ
score changes between treatments (which could include different drugs in the same class) in RCTs of
patients with asthma. See Table E3 in this article’s Online Repository for the list of studies included in this
network. SABA, Short-acting b-agonist.
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calculations of health-related quality of life often was not clearly
reported.
MTC of AQLQ results
The AQLQ was included as an end point in 54 of the 64
blinded RCTs. Fig 2 shows the AQLQ network diagram;
numbered lines indicate the number of studies included in the
comparison (see Table E3 in this article’s Online Repository at
www.jacionline.org for more detailed information on the
individual studies). Higher AQLQ scores indicate better
health-related quality of life, such that increases from baseline
are considered favorable.
During the run-in period, subjects in 9 (17%) RCTs had no
medication (or no run-in period), in 9 (17%) RCTs they received
placebo, and in 36 (66%) RCTs they received an ICS. During
the treatment phase, subjects in 38 (72%)RCTs hadno background
treatment, and in 15 (28%) RCTs they continued ICS use as
background treatment. Overall, 41 (76%) RCTs used the original
AQLQinstrument,whereas 13 (24%)RCTsused alternateversions
(Standardized AQLQ [20%] or MiniAQLQ [4%]).
Study treatment, run-in treatment (none [or no run-in period],
placebo, or ICS), background treatment (none or ICS), AQLQ
type (original or other), and study treatment by background
treatment were statistically significant covariates included in the
final MTC multivariable model for the AQLQ.
Changes in AQLQ scores from baseline
(within-treatment comparisons)
Adjusted AQLQ estimates of change from baseline for
pooled treatment groups in trials with or without background
medication or with different run-in treatments and type of AQLQare presented in detail in Table E4 in this article’s Online
Repository at www.jacionline.org. Fig 3 shows AQLQ score
changes from baseline for situations considered representative
of asthma clinical studies by using the AQLQ original version
and various combinations of run-in period and background
treatment (ie, no run-in treatment and no ICS background,
placebo run-in period and no ICS background, ICS run-in period
and ICS background).
In trials with no run-in period and no concurrent (background)
controller treatment during the treatment period, the estimated
AQLQ changes from baseline achieved in the ICS plus LABA,
ICS, LTRA, and LABA treatment groups were all greater than 0.5
and categorized as large and clinically significant. However,
placebo also achieved a mean improvement greater than 0.5 units
(0.553; 95%CI, 0.367-0.739), which was categorized as probably
clinically significant.
When a run-in period was present during which placebo
was used and there was no concurrent therapy during the active
phase of the trials, the estimated AQLQ change from baseline
was large and clinically significant only for the ICS plus
LABA (0.919; 95% CI, 0.734-1.104) and ICS (0.729; 95% CI,
0.549-0.909) treatment groups. For LTRA (0.504; 95% CI,
0.324-0.685), the increase exceeded 0.5 and was of probable
clinical significance, but LABA treatment alone (0.419; 95% CI,
0.223-0.616) did not exceed the MID threshold and thus was not
clinically significant.
When an ICS formed part of the treatment during the run-in
period and was used as background treatment, the estimated
AQLQ improvements from baseline for the LABA, LTRA, and
omalizumab groups were large and clinically significant;
however, those for theophylline, short-acting b-agonist, and
placebo were also greater than 0.5 units but only fulfilled the
criteria for probable clinical significance (Fig 3).
FIG 3. Adjusted mean change from baseline in overall AQLQ score using the AQLQ original version. SABA,
Short-acting b-agonist.
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Comparison of active versus placebo treatments in patients
with and without background ICSs using the same treatment
during the run-in period are presented in Fig 4. When background
treatment did not include a controller ICS, only ICS plus LABA
and ICS alone achieved a mean improvement of greater than
0.5 units. For ICS plus LABA treatment, the increase was large
and clinically significant (0.729; 95% CI, 0.658-0.799), but for
ICS treatment, the increase was of only probable clinical
significance (0.539; 95% CI, 0.479-0.599). LABAs and LTRAs
added to concurrent ICS treatment achieved increases of only
0.229 (95% CI, 0.135-0.323) and 0.314 (95% CI, 0.230-0.398),
respectively, which were not clinically significant (Fig 4).
When the background concurrent treatment during the active
treatment phase of trials was an ICS, improvements in AQLQ
scores achieved with active treatments relative to placebo were
considerably smaller. With the addition of a LABA (0.349; 95%
CI, 0.271-0.427), LTRA (0.198; 95% CI, 0.127-0.269), or
omalizumab (0.305; 95% CI, 0.202-0.408), the change was not
clinically significant, and theophylline (0.011; 95%CI,20.198 to
0.219) had no effect (Fig 4).Adjusted AQLQ relative effect estimates are presented in Table
E5 in this article’s Online Repository at www.jacionline.org.
Results of sensitivity analyses were generally similar to the
main analysis findings, although the statistical significance of
some covariates included in the models changed. The consistency
tests showed a disagreement between direct and indirect evidence
for the ICS-placebo-LTRA and ICS-LABA-LTRA loops,
indicating that covariate adjustment was justified. However, the
exact level of significance at which to reject the null hypothesis
was no longer .05 because the tested loops and therefore the
consistency test were not independent.19MTC of ACQ results
The ACQ was an end point in 11 of the 64 blinded RCTs. Fig 5
shows the ACQ network diagram; numbered lines indicate the
number of studies included in the comparison (see Table E6 in
this article’s Online Repository at www.jacionline.org for more
detailed information on the individual studies). Lower ACQ
scores indicate better control of asthma symptoms, such that
decreases from baseline are considered favorable.
FIG 4. Differences in adjusted mean change from baseline in overall AQLQ score between treatments
versus placebo. Values are presented for comparisons of active treatments with placebo in trials with the
same design (ie, the same ICS background, the same run-in treatment, and the same AQLQ version). SABA,
Short-acting b-agonist.
J ALLERGY CLIN IMMUNOL
VOLUME 136, NUMBER 4
BATEMAN ET AL 919During the run-in period, all RCTs included ICS treatment;
during the treatment phase, 7 (64%) RCTs had no background
treatment, and 4 (36%) RCTs had ICS background treatment.
Overall, 7 (64%) RCTs used the ACQ original version
(ie, ACQ-7), and 4 (36%) RCTs used the ACQ, 5-item version.
With the exception of study treatment, no statistically significant
covariates were found for inclusion in the model.Changes in ACQ scores from baseline (within-
treatment comparisons)
Fig 6 presents the unadjusted least-squares means by treatment
for the ACQ overall score change from baseline. No studies
showed clinically significant changes in ACQ scores. The effects
on ACQ least-squares mean changes from baseline were
‘‘probably clinically significant’’ (see the Results section in this
article’s Online Repository for details)18 only for the ICS plus
LABA pooled treatment group (20.625; 95% CI, 20.767 to
20.482).Comparisons between treatments
Fig 7 and Table E7 in this article’s Online Repository at
www.jacionline.org present the unadjusted relative treatment
effects of ACQ overall score change from baseline versus
placebo. None of the pooled treatment groups had effects on
ACQ score mean change that exceeded the MID in comparison
with placebo change from baseline. Mean reductions in ACQscores ranged from 20.102 (95% CI, 20.306 to 0.101) for the
addition of theophylline to 20.364 (95% CI, 20.471 to
20.257) for the comparison of LABA plus ICS with ICS alone
(Fig 7). Thus all estimates revealed either no effect or no clinically
significant effect. Results of the sensitivity analyses were similar
to those of the main analysis. The results of these analyses should
be interpreted with caution because of the small sample size and
because no covariate adjustments could be made.DISCUSSION
Our study provides several important insights into the
performance of the AQLQ and ACQ in clinical trials in patients
with asthma. First, it confirms that most established asthma
therapies achieve a clinically significant improvement in the
mean AQLQ score change when compared with baseline values.
Second, it confirms that for all active asthma treatments, the
placebo effect is greatest when there is no run-in period and when
no controller is permitted as concurrent medication during the
study period. Third, improvements in AQLQ score in placebo
arms are also high in studies when ICSs are used during the run-in
period. Thus not surprisingly, compared with placebo treatment
arms, only groups receiving ICS plus LABA achieve a clinically
significant change, and in our analysis the improvement with ICS
achieved only a probably clinically significant level. Finally,
when a second controller is added to ICS treatment (ie, in
comparisons of placebo vs controller added to patients receiving
FIG 5. ACQ network of evidence. Numbers indicate the number of studies with comparisons of ACQ score
changes between treatments (which could include different drugs in the same class) or different drugs in the
same class in RCTs of patients with asthma. See Table E6 in this article’s Online Repository for a list of
studies included in this network. SABA, Short-acting b-agonist.
FIG 6. Adjusted mean change from baseline in overall ACQ score. SABA, Short-acting b-agonist.
J ALLERGY CLIN IMMUNOL
OCTOBER 2015
920 BATEMAN ET ALICSs during the active treatment phase), none of the comparators
achieve a clinically significant or even a probably clinically
significant result.
The results of our analysis of the ACQ are in line with those
for the AQLQ, with none of the differences from placebo
exceeding the MID and ICS-based treatments showing thegreatest effect. However, this conclusion should be interpreted
with caution because of the smaller number of studies suitable
for analysis.
This study has several limitations. Reports of trials do not
present score values in a consistent manner, and baseline score
values were available for only three quarters of the trials. SEs had
FIG 7. Differences in adjusted mean change from baseline in overall ACQ score between treatments versus
placebo. SABA, Short-acting b-agonist.
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(eg, FEV1 and baseline AQLQ score) could not be used as
covariates in the MTC model because of missing values.
Surprisingly, few studies with the ACQ instrument were found
in the literature. In fact, only 1 double-blind RCTof omalizumab
using the ACQ instrument met our inclusion criteria.22 This might
be explained by a reporting bias (ie, underreporting of negative
trial results).
A strength of our study was our attempt to include all reports
containing usable data. Moreover, the inclusion of data for most
accepted controller treatments for asthma provided the
opportunity to compare the results of PROs with the
accepted general efficacy of different classes of treatment. In
general, the relative effects of treatments on AQLQ and ACQ
responses were consistent with their place in treatment
guidelines.
The results raise several questions regarding use of thesewidely
accepted instruments in clinical studies of asthma. Both have been
developed and validated by using standard methodologies and
fulfill the characteristics of an evaluative instrument.2,5,6,10 The
size (0.5 units) of the MID might be questioned. However, the
finding that a 0.5-point change on a 7-point scale is the smallest
change that patients can reliably report has been observed with
other PROs, such as the Chronic Respiratory Disease Question-
naire.5,18,23 Thus it is rather a limitation and threshold of subjective
perception of change than a weakness of the test and appears to be
appropriate for within-subject changes. What is in question is the
use of the MID for comparisons between patients or groups of pa-
tients. Although group mean improvements greater than 0.5 might
be highly desirable, our analysis confirms that this is achieved only
with a favorable trial design that minimizes the placebo effect and
compares ICS or ICS plus LABA with placebo. The prospect of
demonstrating a mean incremental benefit of greater than 0.5
through addition of a second or third controller in addition to an
ICS, other controllers, or both appears remote. In these trials the
Hawthorne effect24 might be particularly pronounced because
improved adherence with background treatment can result in
improvements in all outcomes from baseline and a reduced
opportunity to demonstrate benefit of the new treatment.Faced with this limitation, how is the benefit of new treatments,
particularly treatments that are added to a first- or second-line
controller, to be quantified? Guyatt et al7 advised that even small
mean differences between treatment and control might have an
important effect on patients and that the method for establishing
this proportion is a continuous variable suitable for analysis.
The value of the change to the patients who benefit and to society
or the payer is a different consideration.
The results of our study lend support to the view that these
PROs should be presented in a different way, first as a comparison
of responder rates or as a net treatment benefit analysis (number of
responders less those who deteriorated on the treatment) from
which numbers needed to treat can be calculated. Treatment
comparisons can be further expressed as a ‘‘minimumworthwhile
incremental advantage,’’ which was defined by Jones et al23 as the
percentage of patients in a treated population who experience
improvement at or greater than the MID, which is considered a
worthwhile benefit for the intervention.
Several factors need to be considered in arriving at a minimum
worthwhile incremental advantage. A first consideration is
patient need. The minimum worthwhile incremental advantage
might be small in patients with severe disease (eg, asthma with
frequent exacerbations, some of which might be life-threatening)
in whom any benefit can be considered worthwhile. Consensus
among doctors and discussion with patients can be used to test
the value proposition. Considerations of adverse effects and cost
to patients and society might also be relevant. For subjective
outcomes, discrete-choice modeling techniques might assist in
this decision.25,26
Our study highlights the importance of clinical study design if
the difference between treatments is under study. It is essential to
use methods that reduce the placebo effect seen in patients
receiving an ICS as background treatment during clinical trials.
These include ensuring clinical stability of asthma control
during baseline, longer run-in periods (>_4 weeks), avoidance
of changes in medications for extended periods before and
during the run-in period, and rigorous assessment of treatment
adherence before and after randomization. The use of an
electronic dose-monitoring device might be of value in assessing
J ALLERGY CLIN IMMUNOL
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phases.27 This is of increasing importance in assessing the utility
of more expensive treatments in development for severe asthma.
Initiatives such as the Critical Path Institute, which aims to
develop new PRO tools for use in asthma research, may lead to
instruments that are more responsive to complex interventions,28
but the threshold for the subjective perception of change might
remain a limiting factor.
In conclusion, this network analysis of the magnitude of AQLQ
and ACQ responses achieved with commonly used controllers for
the treatment of persistent asthma confirms that for most
treatments, particularly when controllers are combined, the
mean difference between treatment groups exceeding the MID
is probably not achievable. Future research should focus on
responder analyses and consider an individualized approach
based on the value of the invention for those who respond and
secondarily for society.
We thank Kate Lothman for careful and helpful edits.
Clinical implications: When compared with placebo, only an
ICS, with or without a LABA, achieved the MID. A responder
analysis might be more appropriate for expressing the clinical
benefit of add-on treatments in patients with asthma.REFERENCES
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